ERYTECH confirme son intention de déposer une demande de BLA pour eryaspase dans le traitement des patients atteints de LAL hypersensible

Ads

You May Also Like

Peregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of Bavituximab

TUSTIN, Calif., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a ...

HalioDx : Immunoscore® Colon is available as a CE-IVD solution

Immunoscore® Colon is the first standardized immune-based assay for the classification of cancers Immunoscore® ...